The chemical class referred to as Magea9 Inhibitors would be a collection of compounds that indirectly influence the stability, expression, or function of Magea9 through various cellular mechanisms. These compounds are not specific inhibitors of Magea9 but have the capacity to affect processes that are upstream or downstream of Magea9 function.
Proteasome inhibitors such as Bortezomib, MG132, and Epoxomicin can lead to an accumulation of ubiquitinated proteins, which can increase cellular stress and possibly decrease the stability of proteins like Magea9. Chloroquine and 3-Methyladenine impact lysosomal function and autophagy, respectively, processes that are critical for protein and organelle turnover and may indirectly affect Magea9 levels or activity. LY294002, Rapamycin, PD98059, SB203580, and ZSTK474 all target signaling pathways-PI3K/AKT/mTOR, MAPK/ERK, and p38 MAPK-that can regulate cell growth, survival, and differentiation; changes in these pathways can alter the cellular context in which Magea9 operates. Nutlin-3 can stabilize p53, which in turn can influence the transcription of various genes, potentially including Magea9 or its regulators. Lastly, Trichostatin A affects chromatin structure and gene expression broadly, which can lead to changes in the expression levels of a wide array of proteins, including Magea9. Thus, these compounds represent a diverse array of molecular interventions that can influence Magea9 through their actions on protein stability, gene expression, and cellular signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can lead to increased cellular stress and potentially decrease Magea9 stability. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, potentially affecting Magea9 turnover. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Selective proteasome inhibitor that can alter protein homeostasis and affect Magea9 indirectly. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Lysosomotropic agent that can increase lysosomal pH and affect the degradation of cellular components, potentially influencing Magea9. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Autophagy inhibitor that can prevent the cellular recycling process, potentially impacting Magea9 levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor that can affect downstream signaling pathways, potentially altering Magea9-associated pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor that can affect protein synthesis and autophagy, potentially impacting Magea9 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor that can interfere with the MAPK/ERK pathway, potentially affecting Magea9-related signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor that can alter stress response pathways, potentially influencing Magea9 activity. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
PI3K inhibitor that can disturb various signaling pathways, potentially affecting Magea9 expression. |